You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

SITAVIG Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Sitavig patents expire, and when can generic versions of Sitavig launch?

Sitavig is a drug marketed by Lnhc and is included in one NDA. There are three patents protecting this drug.

This drug has forty-six patent family members in twenty-nine countries.

The generic ingredient in SITAVIG is acyclovir. There are fifty-six drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the acyclovir profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Sitavig

A generic version of SITAVIG was approved as acyclovir by TEVA on April 22nd, 1997.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for SITAVIG?
  • What are the global sales for SITAVIG?
  • What is Average Wholesale Price for SITAVIG?
Summary for SITAVIG
International Patents:46
US Patents:3
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 184
Clinical Trials: 1
Patent Applications: 531
Formulation / Manufacturing:see details
Drug Prices: Drug price information for SITAVIG
What excipients (inactive ingredients) are in SITAVIG?SITAVIG excipients list
DailyMed Link:SITAVIG at DailyMed
Drug patent expirations by year for SITAVIG
Drug Prices for SITAVIG

See drug prices for SITAVIG

Drug Sales Revenue Trends for SITAVIG

See drug sales revenues for SITAVIG

Recent Clinical Trials for SITAVIG

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
BayerPhase 3

See all SITAVIG clinical trials

US Patents and Regulatory Information for SITAVIG

SITAVIG is protected by three US patents.

Patents protecting SITAVIG

Mucoadhesive buccal tablets for the treatment of orofacial herpes
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF HERPES LABIALIS

Mucosal bioadhesive slow release carrier for delivering active principles
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF HERPES LABIALIS

Mucosal bioadhesive slow release carrier for delivering active principles
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF HERPES LABIALIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lnhc SITAVIG acyclovir TABLET;BUCCAL 203791-001 Apr 12, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Lnhc SITAVIG acyclovir TABLET;BUCCAL 203791-001 Apr 12, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Lnhc SITAVIG acyclovir TABLET;BUCCAL 203791-001 Apr 12, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for SITAVIG

See the table below for patents covering SITAVIG around the world.

Country Patent Number Title Estimated Expiration
Russian Federation 2420267 БИОАДГЕЗИВНЫЙ НОСИТЕЛЬ С ЗАМЕДЛЕННЫМ ВЫСВОБОЖДЕНИЕМ ДЛЯ СЛИЗИСТЫХ ОБОЛОЧЕК, ПРЕДНАЗНАЧЕННЫЙ ДЛЯ ДОСТАВКИ АКТИВНЫХ КОМПОНЕНТОВ (BIOADHESIVE CARRIER WITH DELAYED RELEASE FOR MUCOUS MEMBRANES, INTENDED FOR DELIVERY OF ACTIVE COMPONENTS) ⤷  Sign Up
European Patent Office 1998750 VEHICULE BIOADHESIF POUR LES MUQUEUSES POUR DELIVRER LENTEMENT DES PRINCIPES ACTIFS (MUCOSAL BIOADHESIVE SLOW RELEASE CARRIER FOR DELIVERING ACTIVE PRINCIPLES) ⤷  Sign Up
European Patent Office 1837020 Vehicule bioadhesif pour les muqueuses pour delivrer lentement des principes actifs (Mucosal bioadhesive slow release carrier for delivering active principles) ⤷  Sign Up
Portugal 1998750 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SITAVIG

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0809498 SPC/GB10/012 United Kingdom ⤷  Sign Up PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
0809498 10C0038 France ⤷  Sign Up PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.